{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:27:37Z","timestamp":1788852457203,"version":"build-2803163510"},"reference-count":82,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>The role of hyperuricaemia as an independent cardiovascular risk factor remains controversial and subject to debate. Nonetheless, multiple studies have highlighted the central role of uric acid (UA) in conditions such as hypertension, metabolic syndrome, heart failure and coronary artery disease. Various mechanisms have been proposed to explain UA\u2019s involvement in cardiovascular diseases, including through UA-induced oxidative stress, systemic inflammation, endothelial dysfunction and activation of the renin\u2013angiotensin\u2013aldosterone system (RAAS). Asymptomatic hyperuricaemia has been proposed as an independent risk factor for ischaemic heart disease. Nonetheless, the positive impact of urate-lowering therapies on reducing cardiovascular risk still needs to be thoroughly confirmed through large randomised controlled studies.<\/jats:p>","DOI":"10.15420\/ecr.2024.30","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:24:44Z","timestamp":1749824684000},"source":"Crossref","is-referenced-by-count":7,"title":["New Insights into Uric Acid Metabolism in the Pathophysiology of Ischaemic Heart Disease"],"prefix":"10.15420","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-1172","authenticated-orcid":false,"given":"Federica","family":"Piani","sequence":"first","affiliation":[{"name":"Hypertension and Cardiovascular Risk Research Centre, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Annesi","sequence":"additional","affiliation":[{"name":"Hypertension and Cardiovascular Risk Research Centre, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[{"name":"Hypertension and Cardiovascular Risk Research Centre, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol 2020;32:71\u20139. https:\/\/doi.org\/10.1097\/BOR.0000000000000679; PMID:\u00a031688126.","DOI":"10.1097\/bor.0000000000000679"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811\u201321. https:\/\/doi.org\/10.1056\/NEJMra0800885; PMID:\u00a018946066.","DOI":"10.1056\/nejmra0800885"},{"key":"ref2","unstructured":"Dreyfuss F. Hyperuricemia and coronary disease. Harefuah 1959;57:329\u201332 [in Hebrew]. PMID:\u00a013818110."},{"key":"ref3","unstructured":"Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res 2020;12:3167\u201381. PMID:\u00a032774692."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol 2015;77:323\u201345. https:\/\/doi.org\/10.1146\/annurev-physiol-021113-170343; PMID:\u00a025422986.","DOI":"10.1146\/annurev-physiol-021113-170343"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, et al. Uric acid and hypertension: an update with recommendations. Am J Hypertens 2020;33:583\u201394. https:\/\/doi.org\/10.1093\/ajh\/hpaa044; PMID:\u00a032179896.","DOI":"10.1093\/ajh\/hpaa044"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol 2016;213:8\u201314. https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.109; PMID:\u00a026316329.","DOI":"10.1016\/j.ijcard.2015.08.109"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Johnson RJ, Sanchez Lozada LG, Lanaspa MA, et al. Uric acid and chronic kidney disease: still more to do. Kidney Int Rep 2023;8:229\u201339. https:\/\/doi.org\/10.1016\/j.ekir.2022.11.016; PMID:\u00a036815099.","DOI":"10.1016\/j.ekir.2022.11.016"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford) 2017;56:679\u201388. https:\/\/doi.org\/10.1093\/rheumatology\/kew293; PMID:\u00a027498351.","DOI":"10.1093\/rheumatology\/kew293"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Nigam SK, Bhatnagar V. The systems biology of uric acid transporters: the role of remote sensing and signaling. Curr Opin Nephrol Hypertens 2018;27:305\u201313. https:\/\/doi.org\/10.1097\/MNH.0000000000000427; PMID:\u00a029847376.","DOI":"10.1097\/MNH.0000000000000427"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Piani F, Sasai F, Bjornstad P, et al. Hyperuricemia and chronic kidney disease: to treat or not to treat. J Bras Nefrol 2021;43:572\u20139. https:\/\/doi.org\/10.1590\/2175-8239-JBN-2020-U002; PMID:\u00a033704350.","DOI":"10.1590\/2175-8239-jbn-2020-u002"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Borghi C, Piani F. Uric acid and estimate of renal function. Let\u2019s stick together. Int J Cardiol 2020;310:157\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2020.01.046; PMID:\u00a031996303.","DOI":"10.1016\/j.ijcard.2020.01.046"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Casiglia E, Tikhonoff V, Virdis A, et al. Serum uric acid \/ serum creatinine ratio as a predictor of cardiovascular events. Detection of prognostic cardiovascular cut-off values. J Hypertens 2023;41:180\u20136. https:\/\/doi.org\/10.1097\/HJH.0000000000003319; PMID:\u00a036453660.","DOI":"10.1097\/hjh.0000000000003319"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Wang A, Tian X, Wu S, et al. Metabolic factors mediate the association between serum uric acid to serum creatinine ratio and cardiovascular disease. J Am Heart Assoc 2021;10:e023054. https:\/\/doi.org\/10.1161\/JAHA.121.023054; PMID:\u00a034779219.","DOI":"10.1161\/jaha.121.023054"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Gong Y, Tian X, Zhou Y, et al. Association between serum uric acid to serum creatinine ratio and poor functional outcomes in patients with acute ischemic stroke. Eur J Neurol 2022;29:3307\u201316. https:\/\/doi.org\/10.1111\/ene.15521; PMID:\u00a035960656.","DOI":"10.1111\/ene.15521"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Piani F, Agnoletti D, Baracchi A, et al. Serum uric acid to creatinine ratio and risk of preeclampsia and adverse pregnancy outcomes. J Hypertens 2023;41:1333\u20138. https:\/\/doi.org\/10.1097\/HJH.0000000000003472; PMID:\u00a037260263.","DOI":"10.1097\/hjh.0000000000003472"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kawamoto R, Ninomiya D, Akase T, et al. Serum uric acid to creatinine ratio independently predicts incident metabolic syndrome among community-dwelling persons. Metab Syndr Relat Disord 2019;17:81\u20139. https:\/\/doi.org\/10.1089\/met.2018.0055; PMID:\u00a030614758.","DOI":"10.1089\/met.2018.0055"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Jiang L, Jin J, He X, et al. The association between serum uric acid \/ serum creatinine ratio and in-hospital outcomes in elderly patients with acute myocardial infarction. BMC Cardiovasc Disord 2024;24:52. https:\/\/doi.org\/10.1186\/s12872-024-03720-6; PMID:\u00a038229059.","DOI":"10.1186\/s12872-024-03720-6"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Tossetta G, Fantone S, Marzioni D, Mazzucchelli R. Cellular modulators of the NRF2\/KEAP1 signaling pathway in prostate cancer. Front Biosci (Landmark Ed) 2023;28:143. https:\/\/doi.org\/10.31083\/j.fbl2807143; PMID:\u00a037525922.","DOI":"10.31083\/j.fbl2807143"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Xia L, Ma W, Afrashteh A, et al. The nuclear factor erythroid 2-related factor 2\/p53 axis in breast cancer. Biochem Med (Zagreb) 2023;33:030504. https:\/\/doi.org\/10.11613\/BM.2023.030504; PMID:\u00a037841775.","DOI":"10.11613\/bm.2023.030504"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Fantone S, Ermini L, Piani F, et al. Downregulation of argininosuccinate synthase 1 (ASS1) is associated with hypoxia in placental development. Hum Cell 2023;36:1190\u20138. https:\/\/doi.org\/10.1007\/s13577-023-00901-x; PMID:\u00a036995581.","DOI":"10.1007\/s13577-023-00901-x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Fantone S, Piani F, Olivieri F, et al. Role of SLC7A11\/xCT in ovarian cancer. Int J Mol Sci 2024;25:587. https:\/\/doi.org\/10.3390\/ijms25010587; PMID:\u00a038203758.","DOI":"10.3390\/ijms25010587"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Tossetta G, Fantone S, Goteri G, et al. The role of NQO1 in ovarian cancer. Int J Mol Sci 2023;24:7839. https:\/\/doi.org\/10.3390\/ijms24097839; PMID:\u00a037175546.","DOI":"10.3390\/ijms24097839"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Tossetta G, Fantone S, Piani F, et al. Modulation of NRF2\/KEAP1 signaling in preeclampsia. Cells 2023;12:1545. https:\/\/doi.org\/10.3390\/cells12111545; PMID:\u00a037296665.","DOI":"10.3390\/cells12111545"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov 2021;20:689\u2013709. https:\/\/doi.org\/10.1038\/s41573-021-00233-1; PMID:\u00a034194012.","DOI":"10.1038\/s41573-021-00233-1"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis 2018;71:851\u201365. https:\/\/doi.org\/10.1053\/j.ajkd.2017.12.009; PMID:\u00a029496260.","DOI":"10.1053\/j.ajkd.2017.12.009"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 1999;372:285\u201394. https:\/\/doi.org\/10.1006\/abbi.1999.1491; PMID:\u00a010600166.","DOI":"10.1006\/abbi.1999.1491"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Zharikov S, Krotova K, Hu H, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008;295:c1183\u201390. https:\/\/doi.org\/10.1152\/ajpcell.00075.2008; PMID:\u00a018784379.","DOI":"10.1152\/ajpcell.00075.2008"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Tossetta G, Piani F, Borghi C, Marzioni D. Role of CD93 in health and disease. Cells 2023;12:1778. https:\/\/doi.org\/10.3390\/cells12131778; PMID:\u00a037443812.","DOI":"10.3390\/cells12131778"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Piani F, Tossetta G, Cara-Fuentes G, et al. Diagnostic and prognostic role of CD93 in cardiovascular disease: a systematic review. Biomolecules 2023;13:910. https:\/\/doi.org\/10.3390\/biom13060910; PMID:\u00a037371490.","DOI":"10.3390\/biom13060910"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"S\u00e1nchez-Lozada LG, Tapia E, Santamar\u00eda J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237\u201347. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00074.x; PMID:\u00a015610247.","DOI":"10.1111\/j.1523-1755.2005.00074.x"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Yu S, Hong Q, Wang Y, et al. High concentrations of uric acid inhibit angiogenesis via regulation of the Kr\u00fcppel-like factor 2-vascular endothelial growth factor-A axis by miR-92a. Circ J 2015;79:2487\u201398. https:\/\/doi.org\/10.1253\/circj.CJ-15-0283; PMID:\u00a026299712.","DOI":"10.1253\/circj.cj-15-0283"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Grines C, Rubanyi GM, Kleiman NS, et al. Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol 2003;92(9 Suppl 2):24\u201331. https:\/\/doi.org\/10.1016\/s0002-9149(03)00965-2; PMID:\u00a014615023.","DOI":"10.1016\/s0002-9149(03)00965-2"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Xiao J, Zhang XL, Fu C, et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1\u03b2 expression in human primary renal proximal tubule epithelial cells through the toll-like receptor 4-mediated pathway. Int J Mol Med 2015;35:1347\u201354. https:\/\/doi.org\/10.3892\/ijmm.2015.2148; PMID:\u00a025813103.","DOI":"10.3892\/ijmm.2015.2148"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Wang XD, Liu J, Zhang YC, et al. Correlation between the elevated uric acid levels and circulating renin-angiotensin-aldosterone system activation in patients with atrial fibrillation. Cardiovasc Diagn Ther 2021;11:50\u20135. https:\/\/doi.org\/10.21037\/cdt-20-830; PMID:\u00a033708477.","DOI":"10.21037\/cdt-20-830"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Ren H, Qu H, Zhang Y, et al. Detection of monosodium urate depositions and atherosclerotic plaques in the cardiovascular system by dual-energy computed tomography. Heliyon 2024;10:e24548. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24548; PMID:\u00a038304777.","DOI":"10.1016\/j.heliyon.2024.e24548"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"He J, Yang Y, Peng DQ. Monosodium urate (MSU) crystals increase gout associated CHD risk through the activation of NLRP3 inflammasome. Int J Cardiol 2012;160:72\u20133. https:\/\/doi.org\/10.1016\/j.ijcard.2012.05.083; PMID:\u00a022726397.","DOI":"10.1016\/j.ijcard.2012.05.083"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Piani F, Johnson RJ. Does gouty nephropathy exist, and is it more common than we think? Kidney Int 2021;99:31\u20133. https:\/\/doi.org\/10.1016\/j.kint.2020.10.015; PMID:\u00a033390238.","DOI":"10.1016\/j.kint.2020.10.015"},{"key":"ref38","unstructured":"Sarnak MJ, Amann K, Bangalore S, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol 2019;74:1823\u201338. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1017; PMID:\u00a031582143."},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Centola M, Maloberti A, Castini D, et al. Impact of admission serum acid uric levels on in-hospital outcomes in patients with acute coronary syndrome. Eur J Intern Med 2020;82:62\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2020.07.013; PMID:\u00a032709548.","DOI":"10.1016\/j.ejim.2020.07.013"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines. Circulation 2023;148:e9e119. https:\/\/doi.org\/10.1161\/CIR.0000000000001168; PMID:\u00a037471501.","DOI":"10.1161\/CIR.0000000000001183"},{"key":"ref41","unstructured":"Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425; PMID:\u00a031504439."},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Yan X, Gong J, Wang Z, et al. Serum uric acid was non-linearly associated with the risk of all-cause and cardiovascular death in individuals with coronary heart disease: a large prospective cohort study. Front Endocrinol (Lausanne) 2023;14:1278595. https:\/\/doi.org\/10.3389\/fendo.2023.1278595; PMID:\u00a038192419.","DOI":"10.3389\/fendo.2023.1278595"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Wannamethee SG, Papacosta O, Lennon L, Whincup PH. Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: the British Regional Heart Study. Int J Cardiol 2018;252:187\u201392. https:\/\/doi.org\/10.1016\/j.ijcard.2017.11.083; PMID:\u00a029208425.","DOI":"10.1016\/j.ijcard.2017.11.083"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Sedaghat S, Pazoki R, Uitterlinden AG, et al. Association of uric acid genetic risk score with blood pressure: the Rotterdam study. Hypertension 2014;64:1061\u20136. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03757; PMID:\u00a025185132.","DOI":"10.1161\/hypertensionaha.114.03757"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Okura T, Higaki J, Kurata M, et al. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J 2009;73:885\u201391. https:\/\/doi.org\/10.1253\/circj.cj-08-0828; PMID:\u00a019336924.","DOI":"10.1253\/circj.cj-08-0828"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Casiglia E, Tikhonoff V, Virdis A, et al. Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: the URRAH (Uric Acid Right for Heart Health) study. J Hypertens 2020;38:412\u20139. https:\/\/doi.org\/10.1097\/HJH.0000000000002287; PMID:\u00a031644519.","DOI":"10.1097\/hjh.0000000000002287"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;62:170\u201380. https:\/\/doi.org\/10.1002\/acr.20065; PMID:\u00a020191515.","DOI":"10.1002\/acr.20065"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000;10:136\u201343. https:\/\/doi.org\/10.1016\/s1047-2797(99)00037-x; PMID:\u00a010813506.","DOI":"10.1016\/s1047-2797(99)00037-x"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7\u201313. https:\/\/doi.org\/10.7326\/0003-4819-131-1-199907060-00003; PMID:\u00a010391820.","DOI":"10.7326\/0003-4819-131-1-199907060-00003"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988;41:237\u201342. https:\/\/doi.org\/10.1016\/0895-4356(88)90127-8; PMID:\u00a03339376.","DOI":"10.1016\/0895-4356(88)90127-8"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Stack AG, Hanley A, Casserly LF, et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM Int J Med 2013;106:647\u201358. https:\/\/doi.org\/10.1093\/qjmed\/hct083; PMID:\u00a023564632.","DOI":"10.1093\/qjmed\/hct083"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104\u201310. https:\/\/doi.org\/10.1001\/archinte.168.10.1104; PMID:\u00a018504339.","DOI":"10.1001\/archinte.168.10.1104"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894\u2013900. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.703389; PMID:\u00a017698728.","DOI":"10.1161\/circulationaha.107.703389"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Hong C, Zhang Q, Chen Y, et al. Elevated uric acid mediates the effect of obesity on hypertension development: a causal mediation analysis in a prospective longitudinal study. Clin Epidemiol 2022;14:463\u201373. https:\/\/doi.org\/10.2147\/CLEP.S363429; PMID:\u00a035431582.","DOI":"10.2147\/clep.s363429"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003;107:1383\u20139. https:\/\/doi.org\/10.1161\/01.cir.0000056762.69302.46; PMID:\u00a012642358.","DOI":"10.1161\/01.cir.0000056762.69302.46"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Okazaki H, Shirakabe A, Matsushita M, et al. Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care. ESC Heart Fail 2019;6:336\u201343. https:\/\/doi.org\/10.1002\/ehf2.12390; PMID:\u00a030620450.","DOI":"10.1002\/ehf2.12390"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Poss WB, Huecksteadt TP, Panus PC, et al. Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia. Am J Physiol 1996;270:L941\u20136. https:\/\/doi.org\/10.1152\/ajplung.1996.270.6.L941; PMID:\u00a08764218.","DOI":"10.1152\/ajplung.1996.270.6.l941"},{"key":"ref58","unstructured":"Bao F, Yang C, Zhou G. Predictive value of hemoglobin to serum creatinine ratio combined with serum uric acid for in-hospital mortality after emergency percutaneous coronary intervention in patients with acute myocardial infarction. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2023;35:951\u20137 [in Chinese]. https:\/\/doi.org\/10.3760\/cma.j.cn121430-20230418-00291; PMID:\u00a037803954."},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Xi X, Cai J, Zhang C, Wang X. Does serum uric acid to creatinine ratio predict mortality risk in patients with heart failure? Tex Heart Inst J 2024;51. https:\/\/doi.org\/10.14503\/THIJ-23-8210; PMID:\u00a038686683.","DOI":"10.14503\/thij-23-8210"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Piani F, Baschino S, Agnoletti D, et al. Serum uric acid to eGFR ratio correlates with adverse outcomes in elderly hospitalized for acute heart failure. Int J Cardiol 2024;409:132160. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132160; PMID:\u00a038740335.","DOI":"10.1016\/j.ijcard.2024.132160"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Zheng Y, Ou J, Huang D, et al. The U-shaped relationship between serum uric acid and long-term all-cause mortality in coronary artery disease patients: a cohort study of 33,034 patients. Front Cardiovasc Med 2022;9:858889. https:\/\/doi.org\/10.3389\/fcvm.2022.858889; PMID:\u00a035811724.","DOI":"10.3389\/fcvm.2022.858889"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Maloberti A, Biolcati M, Ruzzenenti G, et al. The role of uric acid in acute and chronic coronary syndromes. J Clin Med 2021;10. https:\/\/doi.org\/10.3390\/jcm10204750; PMID:\u00a034682873.","DOI":"10.3390\/jcm10204750"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Tian TT, Li H, Chen SJ, et al. Serum uric acid as an independent risk factor for the presence and severity of early-onset coronary artery disease: a case-control study. Dis Markers 2018;2018:1236837. https:\/\/doi.org\/10.1155\/2018\/1236837; PMID:\u00a030425752.","DOI":"10.1155\/2018\/1236837"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Duran M, Kalay N, Akpek M, et al. High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. Angiology 2012;63:448\u201352. https:\/\/doi.org\/10.1177\/0003319711426868; PMID:\u00a022096206.","DOI":"10.1177\/0003319711426868"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Karaba\u011f Y, Rencuzogullari I, \u00c7a\u011fda\u015f M, et al. Association of serum uric acid levels with SYNTAX score II and long term mortality in the patients with stable angina pectoris who undergo percutaneous coronary interventions due to multivessel and\/or unprotected left main disease. Int J Cardiovasc Imaging 2019;35:1\u20137. https:\/\/doi.org\/10.1007\/s10554-018-1446-6; PMID:\u00a030143922.","DOI":"10.1007\/s10554-018-1446-6"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Yang B, Ma K, Xiang R, et al. Uric acid and evaluate the coronary vascular stenosis gensini score correlation research and in gender differences. BMC Cardiovasc Disord 2023;23:546. https:\/\/doi.org\/10.1186\/s12872-023-03581-5; PMID:\u00a037940848.","DOI":"10.1186\/s12872-023-03581-5"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Hasic S, Kadic D, Kiseljakovic E, et al. Serum uric acid could differentiate acute myocardial infarction and unstable angina pectoris in hyperuricemic acute coronary syndrome patients. Med Arch 2017;71:115\u20138. https:\/\/doi.org\/10.5455\/medarh.2017.71.115-118; PMID:\u00a028790542.","DOI":"10.5455\/medarh.2017.71.115-118"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Hisatome I, Li P, Miake J, et al. Uric acid as a risk factor for chronic kidney disease and cardiovascular disease \u2013 Japanese guideline on the management of asymptomatic hyperuricemia. Circ J 2021;85:130\u20138. https:\/\/doi.org\/10.1253\/circj.CJ-20-0406; PMID:\u00a033342914.","DOI":"10.1253\/circj.cj-20-0406"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Piani F, Agnoletti D, Borghi C. Advances in pharmacotherapies for hyperuricemia. Expert Opin Pharmacother 2023;24:737\u201345. https:\/\/doi.org\/10.1080\/14656566.2023.2197591; PMID:\u00a036999206.","DOI":"10.1080\/14656566.2023.2197591"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.651117; PMID:\u00a017130343.","DOI":"10.1161\/circulationaha.106.651117"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Ogino K, Kato M, Furuse Y, et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010;3:73\u201381. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.868604; PMID:\u00a019933411.","DOI":"10.1161\/circheartfailure.109.868604"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther 2012;30:217\u201326. https:\/\/doi.org\/10.1111\/j.1755-5922.2011.00277.x; PMID:\u00a022099531.","DOI":"10.1111\/j.1755-5922.2011.00277.x"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Konishi M, Kojima S, Uchiyama K, et al. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease. Int J Cardiol 2022;349:127\u201333. https:\/\/doi.org\/10.1016\/j.ijcard.2021.11.076; PMID:\u00a034864084.","DOI":"10.1016\/j.ijcard.2021.11.076"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Grimaldi-Bensouda L, Alp\u00e9rovitch A, Aubrun E, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis 2015;74:836\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202972; PMID:\u00a024395556.","DOI":"10.1136\/annrheumdis-2012-202972"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Lim TK, Noman A, Choy AMJ, et al. The APEX trial: effects of allopurinol on exercise capacity, coronary and peripheral endothelial function, and natriuretic peptides in patients with cardiac syndrome X. Cardiovasc Ther 2018;36:e12311. https:\/\/doi.org\/10.1111\/1755-5922.12311; PMID:\u00a029080386.","DOI":"10.1111\/1755-5922.12311"},{"key":"ref76","unstructured":"Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022;400:1195\u2013205. https:\/\/doi.org\/10.1016\/S0140-6736(22)01657-9; PMID:\u00a036216006."},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Sakuma M, Toyoda S, Arikawa T, et al. Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: a prospective, randomized, open-label, blinded-end-point clinical trial. PLoS One 2022;17:e0261445. https:\/\/doi.org\/10.1371\/journal.pone.0261445; PMID:\u00a035077456.","DOI":"10.1371\/journal.pone.0261445"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Derosa G, Maffioli P, Reiner \u017d, et al. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs 2016;76:947\u201356. https:\/\/doi.org\/10.1007\/s40265-016-0591-2; PMID:\u00a027260336.","DOI":"10.1007\/s40265-016-0591-2"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Bragagni A, Piani F, Borghi C. Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes. Eur Heart J Suppl 2021;23(Suppl E):e40\u20134. https:\/\/doi.org\/10.1093\/eurheartj\/suab094; PMID:\u00a034650352.","DOI":"10.1093\/eurheartj\/suab094"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res 2015;102:63\u201370. https:\/\/doi.org\/10.1016\/j.phrs.2015.09.012; PMID:\u00a026384444.","DOI":"10.1016\/j.phrs.2015.09.012"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Zhang D, Huang QF, Sheng CS, et al. Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers. Blood Press 2021;30:395\u2013402. https:\/\/doi.org\/10.1080\/08037051.2021.1996220; PMID:\u00a034714194.","DOI":"10.1080\/08037051.2021.1996220"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2024.30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:24:52Z","timestamp":1749824692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2024.30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":82,"URL":"https:\/\/doi.org\/10.15420\/ecr.2024.30","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"e18"}}